CDK15/CCNB1(CDK15/cyclin B1)
Sign in to save this workspaceUniProt CDK15: Q96Q40; cyclin B1: P14635 · PDB · AlphaFold (Q96Q40), AlphaFold (P14635) · Substrate: RB Protein + Mn · Clone: (aa103-387)/full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Defactinib | 43.7% | 56.3% | 92.68 | 0.450 |
| 2 | Ponatinib | 32.8% | 67.2% | 78.23 | 0.534 |
| 3 | Pacritinib | 24.2% | 75.8% | 88.64 | 0.452 |
| 4 | Pralsetinib | 23.8% | 76.2% | 93.43 | 0.643 |
| 5 | Pemigatinib | 23.4% | 76.6% | 98.23 | 0.718 |
| 6 | Fedratinib | 14.0% | 86.0% | 96.21 | 0.576 |
| 7 | Pexidartinib | 13.2% | 86.8% | 99.49 | 0.631 |
| 8 | Repotrectinib | 12.4% | 87.6% | 84.21 | 0.608 |
| 9 | Crizotinib | 11.5% | 88.5% | 91.39 | 0.581 |
| 10 | Tucatinib | 11.3% | 88.7% | 99.75 | 0.652 |
| 11 | Tivozanib | 11.2% | 88.8% | 92.42 | 0.673 |
| 12 | Tenalisib | 10.6% | 89.4% | 97.98 | 0.702 |
| 13 | Gedatolisib | 10.5% | 89.5% | 99.75 | 0.611 |
| 14 | Leniolisib | 9.0% | 91.0% | 100.00 | 0.604 |
| 15 | Neratinib | 8.9% | 91.1% | 93.18 | 0.597 |
| 16 | Ceritinib | 8.5% | 91.5% | 95.44 | 0.618 |
| 17 | Abrocitinib | 7.7% | 92.3% | 99.50 | 0.581 |
| 18 | Capmatinib | 7.7% | 92.3% | 99.75 | 0.582 |
| 19 | Futibatinib | 7.6% | 92.4% | 98.48 | 0.718 |
| 20 | Lazertinib | 6.7% | 93.3% | 97.47 | 0.674 |
Paralog block
No paralog group registered for this kinase.
EMT expression
Not in the EMT expression panel.
Selectivity landscape vs inhibition on CDK15/CCNB1
Each point is one of the 92 approved drugs; color = inhibition % on CDK15/CCNB1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…